Saturday 17 October 2026
Export MNOV’s income statement to Excel — free account
MediciNova, Inc.
MNOV Healthcare Biotechnology
MediciNova, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $409,700.00, down 59.0% from fiscal 2023. In the quarter to June 2026, revenue grew 240.6%, EPS grew 28.6% and free cash flow grew 16.8%, each against the same quarter a year earlier.
1.42
0.03
−2.07%
Follow MNOV
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
70.59 | 113.03 | 45.60 | 48.08 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(33.84) | (19.43) | (31.87) | (36.57) | |
P/B ratio |
1.74 | 1.71 | 1.55 | 1.42 | |
Price to Tangible BV |
2.35 | 2.26 | 2.01 | 1.81 | |
EV/Sales |
42.98 | 67.22 | 23.74 | 22.95 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.34) | (4.22) | (3.41) | (3.06) | |
EV/FCF |
(4.34) | (4.22) | (3.41) | (3.06) | |
Quick Ratio |
8.58 | 8.91 | 8.11 | 9.76 | |
Current Ratio |
8.75 | 9.09 | 8.16 | 9.86 | |
Net Debt/EBITDA |
10.02 | 9.65 | 9.98 | 9.65 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.02 | 0.01 | 0.03 | 0.02 | |
Operating CF/Net income |
0.83 | 1.34 | 0.72 | 0.56 | |
Capex/Depreciation |
0.00 | (2.51) | 0.00 | (0.55) | |
Research and Development Expense of Revenue |
224.52% | 675.13% | 1,017.40% | 1,283.86% | |
Selling, General and Administrative Expense of Revenue |
399.17% | 850.37% | 1,024.19% | 1,464.80% | |
Intangible Assets out of Total Assets |
0.24 | 0.22 | 0.21 | 0.20 | |
Share Based Compensation of Revenue |
38.55% | 218.07% | 119.05% | 127.90% | |
Graham Net Nets |
0.35 | 0.37 | 0.42 | 0.47 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(15.91%) | (16.79%) | (18.32%) | (19.69%) | |
Free Cash Flow Yield |
(14.04%) | (14.10%) | (15.27%) | (15.62%) | |
Revenue per Share |
0.01 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.04) | (0.07) | (0.04) | (0.03) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.04) | (0.07) | (0.04) | (0.03) | |
Cash per Share |
0.52 | 0.56 | 0.63 | 0.66 | |
Shareholders Equity per Share |
0.76 | 0.80 | 0.85 | 0.90 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.76 | 0.80 | 0.85 | 0.90 | |
Free Cash Flow |
(1.92) | (3.48) | (2.02) | (1.71) | |
Working Capital |
22.96 | 25.05 | 27.19 | 29.59 | |
Capital Expenditures |
0.00 | (0.01) | 0.00 | 0.00 | |
Net Current Asset Value |
22.76 | 24.85 | 26.97 | 29.31 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.06 | 0.00 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
0.76 | 0.79 | 0.86 | 0.73 | |
Average Assets |
45.13 | 47.57 | 50.74 | 52.85 | |
Average Common Equity |
42.06 | 44.67 | 47.05 | 49.52 |
Columns are period end dates